Stocktoria
COMPASS Pathways plc CMPS
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-09-18
COMPASS Pathways plc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $118.4M | $119.0M | $87.5M | $65.1M | $44.0M |
| Operating income | -$179.0M | -$178.2M | -$136.9M | -$110.4M | -$83.2M |
| Interest expense | — | — | $2.2M | $0 | $0 |
| Income tax | -$2.5M | $1.6M | $780,000 | $408,000 | $199,000 |
| Net income | -$287.9M | -$155.1M | -$118.5M | -$91.5M | -$71.7M |
| EPS (diluted) | $-3.08 | $-2.30 | $-2.32 | $-2.16 | $-1.79 |
| Operating cash flow | -$157.2M | -$119.2M | -$97.4M | -$105.5M | -$67.7M |
| Free cash flow | — | -$119.2M | -$97.4M | -$106.0M | -$68.1M |
| Cash & equivalents | $149.6M | $165.1M | $220.2M | $143.2M | $273.2M |
| Total assets | $210.3M | $213.7M | $276.0M | $197.3M | $300.9M |
| Total liabilities | $263.2M | $59.0M | $50.2M | $16.0M | $16.5M |
| Shareholders' equity | -$52.8M | $154.7M | $225.7M | $181.3M | $284.4M |
Source: SEC EDGAR filings · CIK 0001816590 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.